Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV. Salatino M, et al. Among authors: charreau eh. Oncogene. 2004 Jul 1;23(30):5161-74. doi: 10.1038/sj.onc.1207659. Oncogene. 2004. PMID: 15122317
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV. Labriola L, et al. Among authors: charreau eh. Mol Cell Biol. 2003 Feb;23(3):1095-111. doi: 10.1128/MCB.23.3.1095-1111.2003. Mol Cell Biol. 2003. PMID: 12529413 Free PMC article.
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV. Proietti C, et al. Among authors: charreau eh. Mol Cell Biol. 2005 Jun;25(12):4826-40. doi: 10.1128/MCB.25.12.4826-4840.2005. Mol Cell Biol. 2005. PMID: 15923602 Free PMC article.
Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
Schillaci R, Salatino M, Cassataro J, Proietti CJ, Giambartolomei GH, Rivas MA, Carnevale RP, Charreau EH, Elizalde PV. Schillaci R, et al. Among authors: charreau eh. J Immunol. 2006 Mar 15;176(6):3426-37. doi: 10.4049/jimmunol.176.6.3426. J Immunol. 2006. PMID: 16517711
Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, Elizalde PV. Carnevale RP, et al. Among authors: charreau eh. Mol Endocrinol. 2007 Jun;21(6):1335-58. doi: 10.1210/me.2006-0304. Epub 2007 Apr 17. Mol Endocrinol. 2007. PMID: 17440047
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.
Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Béguelin W, et al. Among authors: charreau eh. Mol Cell Biol. 2010 Dec;30(23):5456-72. doi: 10.1128/MCB.00012-10. Epub 2010 Sep 27. Mol Cell Biol. 2010. PMID: 20876300 Free PMC article.
154 results